Advance in diagnosis-testing technology of Alzheimer's disease
10.3760/cma.j.cn121382-20200410-00513
- VernacularTitle:阿尔茨海默病实验室诊断技术的研究进展
- Author:
Bochen CHE
1
;
Huijuan YIN
;
Jinpeng WU
;
Yingxin LI
Author Information
1. 中国医学科学院生物医学工程研究所，天津 300192
- From:
International Journal of Biomedical Engineering
2020;43(5):412-417,424
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease (AD) is a dementia-type neurodegenerative disease with an increasing incidence in elderly population and a poor prognosis. Therefore, the early diagnosis technology of AD urgently needs to be improved. In this paper, the laboratory diagnostic technologies of Alzheimer's disease were reviewed in the field of neuropsychological assessment, neuroimaging technology, and biomarker detection, including the simple intelligence state scale, the Montreal cognitive assessment scale, the memory and executive function screening scale, structural MRI, and functional MRI, positron emission computed tomography, MRI-based artificial intelligence analysis, and β amyloid (Aβ), homocysteine, S100B protein, Aβ 42, tau protein, urine AD-related neurofilament protein (AD7c-NTP) and Aβ plaques in the retinas. The limitations of these technologies were analyzed, and the development trends of the technologies were summarized. In order to improve the efficiency of AD screening, it is necessary to build an early diagnosis system for AD, in which multimodal diagnosis technology should be used to distinguish different types of AD.
